|
|
| | NEUROMEDIN U-25 (HUMAN) Basic information |
| Product Name: | NEUROMEDIN U-25 (HUMAN) | | Synonyms: | NEUROMEDIN U-25 (HUMAN);NMU-25 (HUMAN);GLY-ASN-HIS-TRP-ALA-VAL-GLY-HIS-LEU-MET-NH2: GNHWAVGHLM-NH2;PHE-ARG-VAL-ASP-GLU-GLU-PHE-GLN-SER-PRO-PHE-ALA-SER-GLN-SER-ARG-GLY-TYR-PHE-LEU-PHE-ARG-PRO-ARG-ASN-NH2;NeuroMedin U-25 (huMan)
NMU-25 (huMan);H-PHE-ARG-VAL-ASP-GLU-GLU-PHE-GLN-SER-PRO-PHE-ALA-SER-GLN-SER-ARG-GLY-TYR-PHE-LEU-PHE-ARG-PRO-ARG-ASN-NH2;Neuromedin U-25 (porcine) trifluoroacetate salt;L-Aspartamide, L-phenylalanyl-L-arginyl-L-valyl-L-α-aspartyl-L-α-glutamyl-L-α-glutamyl-L-phenylalanyl-L-glutaminyl-L-seryl-L-prolyl-L-phenylalanyl-L-alanyl-L-seryl-L-glutaminyl-L-seryl-L-arginylglycyl-L-tyrosyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-arginyl-L-prolyl-L-arginyl- | | CAS: | 312306-89-1 | | MF: | C141H203N41O38 | | MW: | 3080.37 | | EINECS: | | | Product Categories: | Neuromedins and related | | Mol File: | 312306-89-1.mol |  |
| | NEUROMEDIN U-25 (HUMAN) Chemical Properties |
| storage temp. | −20°C | | form | lyophilized powder | | Sequence | Phe-Arg-Val-Asp-Glu-Glu-Phe-Gln-Ser-Pro-Phe-Ala-Ser-Gln-Ser-Arg-Gly-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 |
| | NEUROMEDIN U-25 (HUMAN) Usage And Synthesis |
| Uses | Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds[1][2]. | | References | [1] Mitchell JD, et al., Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. Cardiovasc Res. 2009 Feb 1;81(2):353-61. DOI:10.1093/cvr/cvn302
[2] Alfa RW, et al., Suppression of insulin production and secretion by a decretin hormone. Cell Metab. 2015 Feb 3;21(2):323-334. DOI:10.1016/j.cmet.2015.01.006 |
| | NEUROMEDIN U-25 (HUMAN) Preparation Products And Raw materials |
|